Zosuquidar

From Wikipedia, the free encyclopedia
  (Redirected from LY335979)
Jump to: navigation, search
Zosuquidar
Zosuquidar.svg
Systematic (IUPAC) name
(2R)-​1-​{4-​[(1aR,10bS)-​1,1-​difluoro-​1,1a,6,10b-​tetrahydrodibenzo​[a,e]​cyclopropa​[c]​[7]​annulen-​6-​yl}-​3-​(quinolin-​5-​yloxy)​propan-​2-​ol
Clinical data
Identifiers
167354-41-8 N
None
PubChem CID 153997
ChemSpider 24599682 YesY
UNII AB5K82X98Y YesY
KEGG D06387 YesY
ChEMBL CHEMBL444172 YesY
Chemical data
Formula C32H31F2N3O2
527.61 g/mol
 N (what is this?)  (verify)

Zosuquidar is an experimental antineoplastic drug currently under development. It has completed Phase 3 clinical trials in the United States. It inhibits P-glycoproteins. Other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are trans-membrane proteins that pump foreign substances out of cells in an ATP dependent fashion. Cancers overexpressing P-glycoproteins are able to pump out therapeutic molecules before they are able to reach their target, effectively making the cancer multi-drug resistant. Zosuquidar inhibits P-glycoproteins, inhibiting the efflux pump and restoring sensitivity to chemotherapeutic agents.

References[edit]